Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
21 mai 2018 06h00 HE
|
Tetraphase Pharmaceuticals, Inc.
– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – ...
Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference
09 mai 2018 06h30 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
03 mai 2018 16h30 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
19 avr. 2018 07h00 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
12 avr. 2018 07h00 HE
|
Tetraphase Pharmaceuticals, Inc.
– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ – – Other Key Eravacycline and TP-6076 Data to Also be Highlighted – WATERTOWN, Mass., April ...
Tetraphase Pharmaceuticals to Present at H.C. Wainwright Annual Global Life Sciences Conference
02 avr. 2018 07h00 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference
20 mars 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones
06 mars 2018 16h40 HE
|
Tetraphase Pharmaceuticals, Inc.
Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI Filed NDA in US for IV Eravacycline for cIAI and PDUFA date is August 28th Raised over $65 million through...
Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
01 mars 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
27 févr. 2018 08h00 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...